Favrille pulls plug on lead drug candidate Specifid

BOSTON (MarketWatch) — Biotech group Favrille Inc. said early Tuesday that it was discontinuing development of its lead drug candidate Specifid due to disappointing Phase III clinical results. Favrille had been testing Specifid for the treatment of non-Hodgkin’s lymphoma in conjunction with the therapies Leukine and Rituxan. “We are clearly very disappointed with the data from this trial, particularly on behalf of the patients and their families,” said John Longenecker, Favrille’s chief executive officer, in a statement. “Based on these results, we are discontinuing development of Specifid and are currently evaluating steps to conserve cash and recognize value on our assets,” he added.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Original post by Forextvblog

This entry was posted on Tuesday, May 27th, 2008 at 8:44 am and is filed under Daily Forex Analysis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.